Zymeworks Inc. (ZYME) Income Statement

The revenue trajectory shows a dramatic deceleration from the 2025Q2 peak of $48.7M, which likely reflected a one-time licensing milestone, to essentially no revenue in 2026Q2. This pattern suggests the company's top line is highly dependent on episodic partnership payments rather than recurring product sales, making growth inherently lumpy and unpredictable. Investors should monitor whether new collaboration agreements can replace the expired revenue streams, as the current run-rate implies a return to pre-2024 levels.

The transition from zero COGS to $2.8M in COGS against only $2.4M revenue in 2026Q1 suggests the company may be shifting toward manufacturing or service obligations that carry direct costs, eroding the previously pristine gross margin profile. This negative gross margin is unsustainable and may indicate either a one-time inventory write-down or the beginning of a higher-cost revenue model. The 2026Q2 data showing zero revenue and zero COGS further complicates the picture, as it implies no commercial activity at all.

The operating leverage has turned sharply negative as revenue disappeared while R&D and SG&A expenses remained elevated, with SG&A jumping to $19.3B in 2026Q2 from $15.1B in the prior quarter. This suggests the company is not scaling down its cost structure in response to the revenue decline, potentially indicating strategic investments in pipeline development that have yet to yield commercial returns. The negative operating leverage amplifies losses and underscores the urgency of either securing new partnerships or advancing internal programs to revenue generation.

The cost structure shows R&D as the dominant expense line, historically stable at $30-37M per quarter, which reflects a typical biotech investment in clinical trials and early-stage research. The extraordinary $4.6B R&D figure in 2026Q2 is implausible for a company of Zymeworks' scale and likely represents a non-recurring charge or a data error, but if real, it would signal a dramatic strategic pivot. SG&A also spiked to $19.3B in the same quarter, further suggesting that the reported numbers may include unusual items that obscure the underlying cost discipline.

This quarter likely captured a significant licensing milestone or collaboration payment that temporarily masked the company's underlying cash burn, as evidenced by the $674K operating loss despite the revenue surge. The subsequent decline to $27.6M in 2025Q3 and then to near-zero by 2026Q1 indicates that the revenue was non-recurring and not indicative of a sustainable commercial business. The lasting impact is that Zymeworks' valuation now hinges on its pipeline potential rather than current financial performance, making clinical data readouts the primary catalyst.